Palisade Bio, Inc.

Name: Palisade Bio, Inc. standardized financial statements, quarterly
Creator: Listed

PALINasdaqCIK 1357459HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$500.0k, Q2 FY2026

Operating income−$11.7m, Q2 FY2026

Net income−$10.6m, Q2 FY2026

Palisade Bio, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5
Research and development	$m	not reported	0.4	not reported	not reported	16.0	0.0	not reported	not reported	not reported	not reported	6.0	6.0
Operating income	$m	(3.8)	(3.2)	(3.7)	(4.2)	(3.6)	(3.4)	(2.3)	(2.8)	(2.9)	(10.0)	(10.7)	(11.7)
Interest expense	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(3.6)	(3.0)	(3.5)	(4.1)	(3.5)	(3.3)	(2.2)	(2.8)	(2.9)	(8.9)	(9.6)	(10.6)
Diluted EPS	$ per share	(7.38)	not reported	(4.59)	(3.32)	(2.32)	not reported	(0.47)	(0.58)	(0.38)	not reported	(0.05)	(0.05)
Basic EPS	$ per share	(7.38)	not reported	(4.59)	(3.32)	(2.32)	not reported	(0.47)	(0.58)	(0.38)	not reported	(0.05)	(0.05)

Balance sheet

Cash and equivalents$125.2m, Q2 FY2026

Shareholders' equity$121.7m, Q2 FY2026

Palisade Bio, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	15.3	12.4	11.3	11.4	8.0	9.8	7.2	5.4	5.2	133	133	125
Current assets	$m	16.3	13.3	12.0	12.3	8.9	10.5	7.9	6.4	6.8	134	133	127
Total assets	$m	17.1	14.1	12.7	12.9	9.3	10.9	8.2	6.7	7.0	134	133	127
Current liabilities	$m	2.6	2.6	2.5	2.8	2.7	3.2	2.8	4.0	3.5	4.6	5.6	5.2
Total liabilities	$m	3.0	2.7	2.6	2.9	2.7	3.4	2.9	4.0	3.8	5.0	6.0	5.6
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	14.1	11.3	10.1	9.9	6.6	7.5	5.3	2.6	3.2	129	127	122

Cash flow

Operating cash flow−$7.6m, Q2 FY2026

Capital expenditure$0, Q4 FY2024

Palisade Bio, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(2,662)	(2,746)	(3,180)	(3,499)	(3,133)	(2,381)	(2,333)	(1,817)	(3,553)	(3,144)	(3,890)	(7,603)
Capital expenditure	$k	0.0	0.0	not reported	not reported	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)211.38m, Q2 FY2026

Palisade Bio, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	1.0	0.3	0.4	0.5	0.8	1.2	1.5	4.8	4.8	7.5	210	211

Shares outstanding: 174.27m at Aug 6, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. Listed shows no prices and gives no investment advice.